This website is for US healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

  • Clinicaltrials.gov identifier

    NCT04113018

  • Recruitment Status

    Recruiting

  • First Posted

    October 2, 2019

  • Last update posted

    April 8, 2021

Study Description

Brief summary:

This study is being done because, despite major advances in therapy, MM is still considered an incurable disease. The purpose of this study is to determine the efficacy (how well it works) of the study treatment that combines the following drugs: daratumumab, carfilzomib, lenalidomide, dexamethasone in subjects who have a recent diagnosis of multiple myeloma (MM). Normal plasma (blood) cells are found in the bone marrow and are an important part of the immune system. MM is a cancer formed by malignant (cancerous) plasma cells. Daratumumab, one of the study drugs, is a man-made protein that works with your immune system by attaching itself to the cancerous cells. Once daratumumab attaches itself to these cells, it gets your body's immune system to attack and destroy the MM cells. Daratumumab has shown to be effective in subjects with MM when combined with medicines like bortezomib, or lenalidomide + dexamethasone.

  • Condition or Disease:Multiple Myeloma
  • Intervention/Treatment: Drug: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
  • Phase: Phase 2

Detailed Description

This single arm, two-stage, open-label Phase II study is designed with the primary objective of evaluating the efficacy of induction therapy comprised of 8 cycles of carfilzomib, lenalidomide, dexamethasone and daratumumab (KRd+daratumumab) in terms of complete response or better (CR) in subjects with NDMM, and comparing to relevant historical controls. Post induction, all subjects will undergo disease evaluation, including assessment of minimal residual disease (MRD). Post-induction disease evaluation will be followed by an MRD-based treatment algorithm. This trial will allow us to gather preliminary data on use of MRD status to direct post-induction therapy.

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 39 participants
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: LCI-HEM-MYE-KRdD-001: Phase II Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
  • Actual Study Start Date: November 2019
  • Estimated Primary Completion Date: October 2026
  • Estimated Study Completion Date: October 2026

Arms and interventions

Arm Intervention/treatment
Experimental: 1
Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
Drug: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab
Experimental

Outcome Measures

  • Primary Outcome Measures: 1. Complete Response [ Time Frame: From enrollment to best response; assessed for approximately 5 years ]
    (CR)- Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and <5% plasma cells in bone marrow aspirates
  • Secondary Outcome Measures: 1. Progression Free Survival (PFS) [ Time Frame: From date of treatment start to date of progression or death; assessed for approximately 5 years ]
    PFS is defined as duration of time from enrollment to the study to time of progression or death.
  • 2. Overall Survival (OS) [ Time Frame: From date of enrollment to date of death; assessed for approximately 5 years ]
    OS is defined as the duration from enrollment to the study (treatment start date) to the date of death from any cause. Subjects who are alive or lost to follow-up at the time of the analysis will be censored at the last known date they were alive.
  • 3. Time to Next Treatment (TTNT) [ Time Frame: assessed for approximately 5 years ]
    Time to next treatment (TTNT) will be calculated from the time of treatment start until the start of the first subsequent anti-cancer therapy after all protocol directed therapy is completed. For surviving subjects who do not receive subsequent therapy, TTNT will be censored at the last contact date. For subjects who die before beginning subsequent anti-cancer therapy, TTNT will be censored at the date of death.
  • 4. Duration of Response (DoR) [ Time Frame: assessed for approximately 5 years ]
    Duration of response (DoR) will be calculated for each subject achieving a PR or better and will be calculated from the time of the first assessment that identified response until disease progression or death
  • 5. Time to Disease Progression (TTP) [ Time Frame: From date of start of treatment to date of disease progression; assessed for approximately 5 years ]
    Time to disease progression (TTP) will be calculated in the same fashion as described for PFS with the exception that for subjects who die for causes other than disease progression, TTP will be censored at the date of the other cause mortality.
  • 6. Overall Response (OR) [ Time Frame: From enrollment to best response while on treatment (subjects on induction treatment for approximately 32 weeks) ]

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Subject must meet all of the following applicable inclusion criteria to participate in this
study:

1. Written informed consent and HIPAA authorization for release of personal health
information signed by the subject or his/her legally authorized representative. NOTE:
HIPAA authorization may be included in the informed consent or obtained separately.

2. Age ≥ 18 years at the time of consent.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 (see Appendix A,
Section 18.1) within 28 days prior to day 1 of treatment.

4. Confirmation of newly diagnosed multiple myeloma (NDMM) as per the IMWG 2014 criteria
(see Appendix D, Section 18.4). Newly diagnosed MM patients who may have deferred
transplant are also allowed.

5. Measurable disease present at baseline assessments. Baseline disease assessments are
defined as disease assessments collected within 28 days of initiation of the first
pre-study induction cycle (subjects who received prior therapy) or within 28 days
prior to day 1 of study treatment (subjects with no prior therapy). Measurable disease
is defined as:

1. Serum M-protein ≥ 1 g/dL (> 0.5 g/dL for IgA or IgM) OR

2. Urine M-protein ≥ 200 mg/24 h OR

3. Involved free light chain (FLC) level ≥ 10 mg/dL provided serum FLC ratio is
abnormal

6. No more than one prior cycle of systemic therapy (completed within 6 weeks of consent)
for MM (to accommodate subjects who needed emergent therapy at diagnosis); any prior
radiotherapy must be completed at least 14 days prior to day 1 of treatment. Subject
must have recovered from treatment-induced toxicities to ≤ grade 1 or baseline.

7. Demonstrate adequate organ function within 1 week of day 1 of treatment as defined in
the table below:

Hematological:

- White Blood Cell (WBC) : ≥ 2,000/mm3

- Absolute Neutrophil Count (ANC) : ≥ 1,000/mm3 without growth factors within 1
week of day 1 of treatment

- Hemoglobin (Hgb) : ≥ 8 g/dL

- Platelet count : ≥ 70,000/mm3 if bone marrow plasmacytosis of <50%; otherwise ≥ 50,000/mm3 Renal: Serum creatinine with Creatinine clearance : ≤ 1.5 × upper limit of normal (ULN) with creatinine clearance ≥ 30 mL/min as measured by a 24-hour urine collection or estimated by the Cockcroft - Gault formula ( See formula in Appendix B, Section 18.2 ) Hepatic: - Bilirubin : ≤ 2 × ULN; < 3.0 for subjects with Gilbert's Syndrome - Aspartate aminotransferase (AST) : ≤ 2.5× ULN - Alanine aminotransferase (ALT) : ≤ 2.5 × ULN 8. Adequate cardiac function as defined by ≥ 45% Left Ventricular Ejection Fraction (LVEF) by ECHO or MUGA within 28 days prior to day 1 of treatment. 9. Females of childbearing potential (FCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to day 1 of treatment, and be willing to undergo serial serum or urine pregnancy testing. NOTE: Females are considered of child bearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause). 10. FCBP must be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of 1% per year] or highly
effective) from the time of informed consent until 3 months after the last protocol
prescribed therapy (which also includes FCBP on carfilzomib) has been discontinued.
NOTE: estrogens may further increase the risk of thrombosis (beyond that associated
with lenalidomide) and their use should be based on a benefit-risk decision. For the
highly effective contraceptive method, a method with low user dependency is preferable
but not required (see tables, adapted from:
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2
014_09_HMA_CTFG_Contraception.pdf)

Highly Effective Birth Control Methods:

- combined (estrogen and progestogen containing) hormonal contraception associated
with inhibition of ovulation

- oral

- intravaginal

- transdermal

- progestogen-only hormonal contraception associated with inhibition of ovulation

- oral

- injectable

- implantable (Contraception method considered to have low user dependency)

- intrauterine devide (IUD) (Contraception method considered to have low user
dependency)

- intrauterine hormone-releasing system (IUS) (Contraception method considered to
have low user dependency)

- vasectomised partner (Contraception method considered to have low user
dependency) Vasectomised partner is a highly effective birth control method
provided that partner is the sole sexual partner of the FCBP trial participant

- sexual abstinence (Sexual abstinence is considered a highly effective method only
if defined as refraining from heterosexual intercourse during the entire period
of risk associated with the study treatments)

Acceptable Birth Control Methods:

- Progestogen-only oral hormonal contraception, where inhibition of ovulation is
not the primary mode of action

- Male or female condom with or without spermicide (A combination of male condom
with either cap, diaphragm or sponge with spermicide (double barrier methods) are
also considered acceptable, but not highly effective, birth control methods.

11. Male subjects (even those who have had a vasectomy) who are sexually active with a
FCBP must be willing to use latex or synthetic condoms from initiation of study
treatment until 3 months after the last protocol prescribed therapy has been
discontinued. They must also refrain from donating sperm for at least 90 days after
the last dose of carfilzomib and at least 90 days from the last dose of daratumumab.
The FCBP partner should also consider contraception recommendations (see inclusion
#10).

12. As determined by the enrolling physician, ability of the subject to understand and
comply with study procedures for the entire length of the study.

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

1. Any infection requiring systemic therapy (i.e. involving IV antibiotics) (NOTE: at
discretion of investigator, subjects with uncomplicated urinary tract infections may
be eligible).

2. Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the
mother is being treated on study, and any female subject must agree not to donate eggs
during the study and for 3 months after the last protocol prescribed therapy has been
discontinued).

3. Has a known additional malignancy that is active and/or progressive requiring
treatment; exceptions include basal cell or squamous cell skin cancer, in situ
cervical or bladder cancer, carcinoma of the prostate with a current PSA value of <0.5 ng/mL or other cancer for which the subject has completed treatment, been disease-free for at least five years, and is considered by Sponsor-Investigator to be at <30% risk of relapse, or on hormonal therapy for a history of either prostate cancer or breast cancer, provided that there has been no evidence of disease progression during the previous three years. 4. Non-secretory MM. 5. Active involvement of the central nervous system by MM. 6. Prior cardiovascular cerebrovascular accident with persistent neurological deficit. 7. Has chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal. FEV1 is required for subjects suspected of having chronic obstructive pulmonary disease and are not eligible if FEV1 is 70 years old only: Defined frail, per IMWG criteria
of 'frailty'. Frailty assessment does not need to be performed unless the subject is
transplant ineligible and > 70 years old. "Frail" is defined as a frailty score of ≥
2.

18. Prior or current exposure to daratumumab or other anti-CD-38 therapies.

19. Focal radiation therapy within 14 days prior to C1D1 with the exception of palliative
radiotherapy for symptomatic management but not on measurable extramedullary
plasmacytoma.

Contacts and Locations

Contacts

Contact: Ashley Franklin 980-442-2315 ashley.franklin@atriumhealth.org

Locations

United States, North Carolina
Levine Cancer Institute
Charlotte

Sponsors and Collaborators

Saad Z. Usmani, MD

Amgen

Celgene

Janssen, LP

Investigators

Principal Investigator: Saad Usmani, MD Atrium Health

More Information

  • Responsible Party: Saad Z. Usmani, MD
  • ClinicalTrials.gov Identifier: NCT04113018 History of Changes
  • Other Study ID Numbers: LCI-HEM-MYE-KRDD-001, 00037709
  • First Posted: October 2, 2019 Key Record Dates
  • Last Update Posted: April 8, 2021
  • Last Verified: April 2021
  • Studies a U.S. FDA-regulated Drug Product: Yes
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Neoplasms, Plasma Cell Multiple Myeloma